Our study suggests that rare variation in genes including AMPD3, MICAL2, DPP6, and DENND2B may play a role in subclinical atherosclerosis, thereby making them promising novel candidates for the development of anti-atherosclerotic therapies. This evidence concerns the gene DPP6 and atherosclerosis.